by Usha Govindarajulu | Apr 13, 2022 | Biostatistics, Blog, COVID-19, Healtcare, Usha Govindarajulu
Issues in COVID-19 research and statistical analyses (Part XVVVIII) April 13, 2022 In one of the latest Scientific American article, “What We Know about Omicron’s BA.2 Variant So Far”, the article summarizes some of the latest research about this new COVID-19 variant,...
by Usha Govindarajulu | Mar 30, 2022 | Biostatistics, Blog, COVID-19, Epidemiology, Healtcare, Usha Govindarajulu
March 30, 2022 Latest research published in the Lancet shows diabetes onset was higher for those with post-acute sequelae or long-haul COVID-19 however these may be preliminary results. The results came from a cohort study which used databases from the United States...
by Usha Govindarajulu | Mar 16, 2022 | Biostatistics, Blog, COVID-19, Epidemiology, Healtcare, Usha Govindarajulu
March 15, 2022 In a recent article in The Scientist than appeared back in January, they mentioned using several pre-print articles which are cited for this article. In one of the pre-print articles by Adamson et al published on March 5 about a very recent small study...
by Usha Govindarajulu | Jan 7, 2022 | Biostatistics, Blog, COVID-19, Healtcare
January 5, 2022 With the ongoing rise in COVID-19 cases due to the Omicron variant of Sars-Cov-2, we searched for some actual studies on the change in vaccine efficacy due to Omicron exposure. In one pre-print article, Buchan et al studied 3,442...
by Usha Govindarajulu | Nov 26, 2021 | Biostatistics, Blog, COVID-19, Healtcare, Professor, Usha Govindarajulu
At home Antigen tests statistical results November 24, 2021 Antigen tests for SARS-CoV-2 are back and are pending more approvals by the current administration. If so, they may be used more often and more frequently to help people get back to a more normal lifestyle....
by Usha Govindarajulu | Nov 10, 2021 | Biostatistics, Blog, Healtcare, Usha Govindarajulu
Pfizer anti-viral November 10, 2021 Pfizer, similar to Merck, has announced the efficacy of their anti-viral drug called PAXLOVID against SARS-CoV-2. The reported 89% efficacy against serious disease and 100% efficacy against death and they are making headlines....